Growing Use of Biosimilar in Treating IBD; Efficacy and Cost-Effectiveness to Be Major Demand Drivers
Inflammatory bowel disease (IBD) is an idiopathic inflammatory disease of the gastrointestinal system which is chronic in nature. The disease is of predominantly two types, Crohn's disease and ulcerative colitis. The treatment of IBD has been transforming with new treatment alternatives in use. The ending patent period of drugs give rise to the production of similar biologics that are commercialized at a lower price than the innovator biologics. These drugs are known as biosimilars which are biologic products similar to...
View full press release